Johnson & Johnson (JNJ)
Pretax margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) | US$ in thousands | 36,889,000 | 21,725,000 | 22,776,000 | 16,497,000 | 17,328,000 |
Revenue | US$ in thousands | 84,021,000 | 79,428,000 | 93,356,000 | 82,174,000 | 81,474,000 |
Pretax margin | 43.90% | 27.35% | 24.40% | 20.08% | 21.27% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $36,889,000K ÷ $84,021,000K
= 43.90%
Johnson & Johnson's pretax margin has shown a downward trend over the past five years, declining from 21.12% in December 2019 to 17.69% in December 2023. This indicates that the company's ability to generate profits before accounting for taxes has weakened over time. Factors contributing to this decline could include changes in revenue, operating expenses, or the overall competitive landscape within the industry. Further analysis is recommended to identify the specific reasons behind this trend and to assess the company's overall financial performance and prospects.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Johnson & Johnson
JNJ
43.90%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
15.74%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
7.94%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%